<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04799210</url>
  </required_header>
  <id_info>
    <org_study_id>CIP2020-001</org_study_id>
    <nct_id>NCT04799210</nct_id>
  </id_info>
  <brief_title>Human Factors Actual-Use Clinical Protocol</brief_title>
  <acronym>CONTAIN</acronym>
  <official_title>Human Factors Actual-Use Confirmatory Validation Study of the Eximis CS (Contained Segmentation) System (&quot;Contain&quot; Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eximis Surgical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eximis Surgical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm device use safety and effectiveness of the Eximis CS&#xD;
      (Contained Segmentation) System in actual use by representative users, use, and use&#xD;
      environments as required for regulatory agency clearance for commercial use.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, single-arm study to confirm device use safety and&#xD;
      effectiveness in an actual use setting when utilized by gynecological surgeons during surgery&#xD;
      for containment, segmentation and extraction of uterine tissue in pre-menopausal women&#xD;
      undergoing laparoscopic hysterectomy or myomectomy for non-cancer indications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single Group Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of procedures where all critical tasks related to the Eximis CS are performed without serious use error.</measure>
    <time_frame>Through study completion, anticipated to be 4-6 months</time_frame>
    <description>Primary Endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of procedures successfully completed with use of the Eximis CS device.</measure>
    <time_frame>Through study completion, anticipated to be 4-6 months</time_frame>
    <description>Secondary Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Capture Bags with breach of containment.</measure>
    <time_frame>Through study completion, anticipated to be 4-6 months</time_frame>
    <description>Secondary Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number and severity of user adverse events caused by use error.</measure>
    <time_frame>Day of surgery</time_frame>
    <description>Secondary Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number and severity of subject adverse events caused by use error.</measure>
    <time_frame>Minimum 30 days (Standard of care follow-up 4-6 weeks)</time_frame>
    <description>Secondary Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All other adverse events.</measure>
    <time_frame>Minimum 30 days (Standard of care follow-up 4-6 weeks)</time_frame>
    <description>Secondary Endpoint</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Duration of the segmentation/extraction procedure (from insertion of the Eximis CS deployment instrument into the abdomen until removal of the Eximis CS Capture Bag from the abdomen).</measure>
    <time_frame>Day of surgery</time_frame>
    <description>For Informal Evaluation</description>
  </other_outcome>
  <other_outcome>
    <measure>Duration of the surgical procedure (from skin incision to skin closure).</measure>
    <time_frame>Day of surgery</time_frame>
    <description>For Informal Evaluation</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of incision (mm) used for the Eximis CS device at procedure end (removal of Eximis CS Capture Bag).</measure>
    <time_frame>Day of surgery</time_frame>
    <description>For Informal Evaluation</description>
  </other_outcome>
  <other_outcome>
    <measure>Removed tissue weight (grams).</measure>
    <time_frame>Day of surgery</time_frame>
    <description>For Informal Evaluation</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of extracted tissue segments per subject.</measure>
    <time_frame>Day of surgery</time_frame>
    <description>For Informal Evaluation</description>
  </other_outcome>
  <other_outcome>
    <measure>The size (mm) of the largest segment will be recorded, defined as the segment with the largest cross-sectional area of the surface that is parallel with the incision opening.</measure>
    <time_frame>Day of surgery</time_frame>
    <description>For Informal Evaluation</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's pathology results of the extracted tissue and pathologist assessment of radiofrequency (RF) energy impact to the tissue, if any, from use of the Eximis CS device.</measure>
    <time_frame>Day of surgery</time_frame>
    <description>For Informal Evaluation</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Laparoscopic Gynecological Surgery</condition>
  <arm_group>
    <arm_group_label>Human Factors Actual Use</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Confirm device use safety and effectiveness of the Eximis CS (Contained Segmentation) System in actual use</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Eximis CS (Contained Segmentation) System</intervention_name>
    <description>Containment, segmentation and extraction of uterine tissue in pre-menopausal women undergoing laparoscopic hysterectomy or myomectomy for non-cancer indications.</description>
    <arm_group_label>Human Factors Actual Use</arm_group_label>
    <other_name>Eximis CS</other_name>
    <other_name>EX-900K-CLIN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt;/= 21 and &lt; 50 years.&#xD;
&#xD;
          2. Planned laparoscopic hysterectomy or myomectomy.&#xD;
&#xD;
          3. Tissue specimen is &lt;11 cm in maximum diameter based on standard preoperative&#xD;
             assessment.&#xD;
&#xD;
          4. Pre-operative evaluation which may include imaging, cervical cancer screening, and&#xD;
             endometrial biopsy has been completed.&#xD;
&#xD;
          5. Signed informed consent.&#xD;
&#xD;
          6. Willing to adhere to protocol requirements and complete follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject is post-menopausal, defined as amenorrhea &gt;12 months in the absence of&#xD;
             ovulation suppression.&#xD;
&#xD;
          2. Known or suspected malignancy of gynecological origin as determined by standard&#xD;
             clinical practice.&#xD;
&#xD;
          3. Candidate for en bloc tissue removal, for example through the vagina or via a&#xD;
             mini-laparotomy incision.&#xD;
&#xD;
          4. Hemoglobin &lt; 8 g/dl within 30 days prior to surgery.&#xD;
&#xD;
          5. Subject has a current history of undiagnosed genital bleeding.&#xD;
&#xD;
          6. Subject has an implanted electronic device where use of radiofrequency (RF) energy&#xD;
             would be contraindicated (e.g., pacemaker, internal defibrillator).&#xD;
&#xD;
          7. Medical condition, surgical history, or intra-operative findings, which in the option&#xD;
             of the investigator, precludes utilization of the Eximis CS System.&#xD;
&#xD;
          8. Known allergy to polyurethane, polyethylene, thermoplastic fluoropolymer and/or&#xD;
             chlorinated polyvinyl chloride.&#xD;
&#xD;
          9. Concurrent participation in another therapeutic or interventional clinical trial with&#xD;
             investigational pharmaceutical agent(s) or medical device(s) that could impact&#xD;
             evaluation of this study as determined by the Investigator.&#xD;
&#xD;
         10. Inability to comply with the study procedures or follow-up in the opinion of the&#xD;
             investigator.&#xD;
&#xD;
         11. Subject is pregnant.&#xD;
&#xD;
         12. Intraoperative Exclusion: Abdominal wall thickness at the umbilicus incision site is &gt;&#xD;
             8 cm.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pre-menopausal women undergoing laparoscopic hysterectomy or myomectomy for non-cancer indications.</gender_description>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sawsan As-Sanie, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Women's Hospital, University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beth Crump, RN, BSN</last_name>
    <phone>303 981-1120</phone>
    <email>beth.crump@eximissurgical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Ross</last_name>
    <phone>303 818 6315</phone>
    <email>julie.ross@eximissurgical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Advanced Women's Health Institute</name>
      <address>
        <city>Greenwood Village</city>
        <state>Colorado</state>
        <zip>80111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Moore, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AdventHealth Medical Group Gynecologic Surgery at Celebration</name>
      <address>
        <city>Celebration</city>
        <state>Florida</state>
        <zip>34747</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Stockwell, DO, FACOG</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Swor Women's Care</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Swor, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystem</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Tu, MD, MPH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Gynecologic Surgery Institute</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charles Miller, MD, FACOG</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney S Lim, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ProMedica Health System</name>
      <address>
        <city>Sylvania</city>
        <state>Ohio</state>
        <zip>43560</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Wahl, MD, FACOG</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

